April 2025 - Page 14 of 14

Dr. Sarah Psutka MD MSc presents interim results from the SunRISe-4 trial at EAU25

By Mourabit Halima 2025.04.04

At the EAU25 Congress, Dr. Sarah Psutka MD MSc shared promising data from the SunRISe-4 trial evaluating neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer (MIBC) who are…

EAU25 | Dr. Dr. med. Yannic Volz Presents the PRACTICE Study: Can Prehabilitation Improve Radical Cystectomy Outcomes?

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Yannic Volz (Ludwig-Maximilians-Universität München) introduced early insights from the ongoing PRACTICE trial (NCT06806059), a randomized, single-blinded study assessing the impact of structured physical activity before radical cystectomy…

EAU25 | Sustainability in Uro-Oncology: Comparing the Carbon Footprint of RC vs CRT

By Peng Longmei 2025.04.03

At #EAU25, Dr. Vera R. and colleagues from Erasmus MC presented the first study to assess the environmental impact and staff requirements of radical cystectomy (RC) versus chemoradiation (CRT) for…

EAU25 | Dr. Seth Lerner Shares First-in-Human Results on Bel-sar (AU-011) in NMIBC

By Mourabit Halima 2025.04.03

At #EAU25, Dr. Seth Lerner (Baylor College of Medicine) presented early findings from a Phase 1 study (NCT05483868) evaluating Bel-sar (AU-011)—a novel virus-like drug conjugate (VDC) for non-muscle invasive bladder…

EAU25 | Dr. Nikhil Mayor Presents NeuroSAFE PROOF Trial: Advancing Nerve-Sparing in Prostate Cancer Surgery

By Mourabit Halima 2025.04.01

At #EAU25, Dr.Nikhil Mayor (Imperial College London) presented results from the NeuroSAFE PROOF trial (NCT03317990)—the first randomized, controlled, single-blinded study comparing NeuroSAFE-guided versus standard robot-assisted radical prostatectomy (RARP) in localized…

EAU25 | NeuroSAFE PROOF Trial: Enhancing Functional Outcomes in Prostate Cancer Surgery

By Lisa Cui 2025.04.01

At #EAU25, Dr. Ricardo Almeida Magana (UCL, London) presented compelling data from the NeuroSAFE PROOF trial, a multicenter, randomized phase 3 study evaluating the role of intraoperative frozen section analysis…

EAU25 | PERSIAN Trial: Can SBRT Enhance Systemic Therapy in Oligometastatic mHSPC?

By Mourabit Halima 2025.04.01

At #EAU25, Dr. Giulio Francolini and colleagues presented early results from the ongoing PERSIAN trial (NCT03449719) a randomized phase II study investigating the addition of stereotactic body radiotherapy (SBRT) to…

EAU25 | PEACE-3 Trial Update: Bone-Protective Agents Improve Outcomes in mCRPC

By Peng Longmei 2025.04.01

At #EAU25, Dr. Fred Saad presented new insights from the PEACE-3 trial (NCT02194842), a multicenter study evaluating enzalutamide ± radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) and bone…

APASL 2025 Congress Chair: Dr. Lai Wei, Beijing Tsinghua Changgung Hospital

By Mourabit Halima 2025.04.01

Highlights of the Congress The 34th Annual Meeting of the Asia-Pacific Association for the Study of the Liver (APASL) concluded successfully in Beijing on March 30, 2025. Under the theme…